Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKF7 is a proprietary, standardized bio-extract of the Labisia pumila plant (also known as Kacip Fatimah), native to Malaysia. It is developed as a botanical therapeutic for obesity and metabolic disorders. Preclinical and clinical studies indicate that SKF7 reduces body weight, BMI, waist circumference, and waist-to-height ratio in individuals with obesity. The mechanism of action appears to involve inhibition of visceral fat accumulation and normalization of blood glucose and lipid profiles. The extract contains polyphenols such as gallic acid which have demonstrated anti-inflammatory activity through inhibition of enzymes like elastase and COX-2. SKF7 has been approved as a traditional medicine in Malaysia, Indonesia, Singapore, received FDA clearance in the US as a dietary supplement (not pharmaceutical drug), and is under further development for potential use against diabetes, cancer, and COVID-19.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SKF7.